Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

GON-block in Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study (DHC-GON-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02686983
Recruitment Status : Unknown
Verified February 2016 by Jakob Møller Hansen, MD., Danish Headache Center.
Recruitment status was:  Not yet recruiting
First Posted : February 22, 2016
Last Update Posted : February 23, 2016
Sponsor:
Information provided by (Responsible Party):
Jakob Møller Hansen, MD., Danish Headache Center

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Infiltration of the greater occipital nerve (GON) with local anaesthetics and corticosteroids is a treatment option for cluster headache. Corticosteroids may be helpful in reducing the pain intensity and frequency in chronic migrtaine. This RCT is set up to assess efficacy and safety of sub-occipital steroid injections with local anesthetic in patients with chronic migraine.

Condition or disease Intervention/treatment Phase
Chronic Migraine Drug: Betamethasone and local anesthetic Phase 4

Detailed Description:
Infiltration of the greater occipital nerve (GON) with local anaesthetics and corticosteroids is a treatment option for cluster headache. In general, there is a marked paucity of evidence concerning GON blocks in migraine. Corticosteroids may be helpful in reducing the pain intensity and frequency in these patients. This is an RCT to assess efficacy and safety of sub-occipital steroid injections with local anesthetic in patients with chronic migraine.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 34 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Greater Occipital Nerve Blockade for the Treatment of Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study
Study Start Date : March 2016
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : July 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Headache Migraine

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Active
Betamethasone and local anesthetic.
 Drug: Betamethasone and local anesthetic
Infiltration of the greater occipital nerve .
Other Name: GON block
Placebo Comparator: Placebo
Saline with local anesthetic.
 Drug: Betamethasone and local anesthetic
Infiltration of the greater occipital nerve .
Other Name: GON block


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of migraine days [ Time Frame: 8 weeks ]
    Number of days fulfilling the ICHD criteria for migraine


Secondary Outcome Measures :
  1. Number of days with severe headache days [ Time Frame: 8 weeks ]
    Number of days with severe headache days

  2. Medication use [ Time Frame: 8 weeks ]
    use of medication recorded during the 8 weeks

  3. Responder rate [ Time Frame: 8 weeks ]
    number of patients with more than 50% reduction in migraine

  4. Number of migraine attacks [ Time Frame: 8 weeks ]
    Number of attacks fulfilling the ICHD criteria for migraine


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chronic migraine

Exclusion Criteria:

  • Medication overuse headache
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02686983


Contacts
Layout table for location contacts
Contact: Jakob Møller Hansen jamoha01@regionh.dk

Locations
Layout table for location information
Denmark
Danish Headache Center, University of Copenhagen, Faculty of Health Sciences, Department of Neurology, Glostrup Hospital
Glostrup, Copenhagen, Denmark, 2600
Sponsors and Collaborators
Jakob Møller Hansen, MD.
Investigators
Layout table for investigator information
Principal Investigator: Jakob M Hansen, MD, PhD Danish Headache Center
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: Jakob Møller Hansen, MD., MD, PhD, Danish Headache Center
ClinicalTrials.gov Identifier: NCT02686983    
Other Study ID Numbers: DHC-GON-1
First Posted: February 22, 2016    Key Record Dates
Last Update Posted: February 23, 2016
Last Verified: February 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Betamethasone
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Betamethasone benzoate
Anesthetics
Anesthetics, Local
 Betamethasone sodium phosphate
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Anti-Asthmatic Agents
Respiratory System Agents